Adaptive Biotechnologies is trading 4.18% higher at $25.43, with no clear company-specific catalyst identified for the October 23 move. - Biotech was weaker, with XBI down 2.08%, while major indexes were mixed to lower; broader market conditions do not clearly explain the gain. - The shares appear to be moving against that backdrop, and the cause remains unclear. The next scheduled results are November 4.